Amy Suzon Chappell MD

PubMed

• 2 citations
  Toward a Lifestyle Medicine Approach to Illness Anxiety Disorder (Formerly Hypochondriasis).
  Amy S Chappell
  American Journal of Lifestyle Medicine. 2018-04-27
• 98 citations
  The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations
  Shannon M. Smith, Robert H. Dworkin, Dennis C. Turk, Ralf Baron, Michael Polydefkis
  The Journal of Pain. 2017-07-01
• 20 citations
  Occupancy of Nociceptin/Orphanin FQ Peptide Receptors by the Antagonist LY2940094 in Rats and Healthy Human Subjects.
  Eyas Raddad, Amy Chappell, J Meyer, Alan A. Wilson, Charles Edward Ruegg
  Drug Metabolism and Disposition. 2016-09-01

Journal Articles

• Efficacy and Safety of Talampanel in Patients with Amyotrophic Lateral Sclerosis  
  Amy S.Chappell, Robert Pascuzzi, John Bjerke, Jeff Rothstein, Amyotrophic Lateral Sclerosis Journal, 1/1/2009
• Tailoring chronic pain treatments for the elderly: Are we prepared for the challenge?  
  Stephen P. Arneric, Jennifer M.A. Laird, Amy S. Chappell and Jeffrey D. Kennedy., Drug Discovery Today, 1/1/2013
• Evaluation of patient-rated stiffness associated with fibromyalgia: a post-hoc analysis of 4 pooled, randomized clinical trials of duloxetine  
  Bennett R. Russell IJ. Choy E. Spaeth M. Mease P. Kajdasz D. Walker D. Wang F. Chappell A., Clinical Therapeutics, 1/1/2012
• A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis  
  Chappell AS. Desaiah D. Liu-Seifert H. Zhang S. Skljarevski V. Belenkov Y. Brown JP., Pain Practice, 1/1/2011
• Estimation of minimum clinically important difference for pain in fibromyalgia  
  Mease PJ. Spaeth M. Clauw DJ. Arnold LM Bradley LA. Russell IJ. Kajdasz DK. Walker DJ. ChappellAS., Arthritis care and Research, 1/1/2011
• Efficacy of Duloxetine in Patients with Chronic Pain Conditions  
  Sjklarevski V, Zhang S,Iyengar S, D’Souza D, Alaka K, Chappell A, Wernicke J, Current Drug Therapy, 1/1/2011
• Maintenance of effect of duloxetine in patients with chornic low back pain: a 41 week uncontrolled, dose-blinded study  
  Skljarevski V. Zhang S. Chappell AS. Walker DJ. Murray I. Backonja M., Pain Medicine, 1/1/2010
• The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetin...  
  Farrar JT. Pritchett YL. Robinson M. Prakash A. Chappell A., Journal of Pain, 1/1/2010
• Effect of duloxetine in patients with fibromyalgia: tiredness subgroups  
  Bradley LA. Bennett R. Russell IJ. Wohlreich MM. Chappell AS. Wang F. D’Souza DN. Moldolfsky H., Arthritis Research and Therapy, 1/1/2010
• Efficacy and Safety of duloxetine in patients with chronic low back pain  
  Skljarevski V. Desaiah D. Liu-Seyfert H. Zhang Q. Chappell AS. Detke MJ. Iyengar S. Atkinson JH. Backjona M., Spine, 1/1/2010
• Long term safety, tolerability and efficacy of duloxetine in the treatment of fibromyalgia  
  Mease PJ. Russell IJ. Kajdasz DK. Wiltse CG. Detke MJ. Wolhreich MM. Walker DJ. Chappell AS., Seminars in Arthritis and Rheumatism, 1/1/2010
• A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain  
  Skljarevski V. Ossanna M. Liu-Seifert H. Zhang Q. Chappell A. Iyengar S. Detke M. Backonja M., European Journal of Neurology, 1/1/2009
• Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain  
  Skljarevski V, Desaiah D, Zhang Q, Chappell AS, Detke M, Gross j, Ziegler D, Diabetes/Metabolism Research and Reviews, 1/1/2009
• A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia  
  Chappell AS. Littlejohn G. Kajdasz DK. Scheinberg M. D'Souza DN. Moldofsky H., Clinical Journal of Pain, 1/1/2009
• Brain Functional Changes and Duloxetine Treatment Response in Fibromyalgia: A Pilot Study  
  Aimee M. Hunter, PhD, Andrew F. Leuchter, MD, Ian A. Cook, MD, Michelle Abrams, RN, Barbara E. Siegman, MA, R.EEG.T., Daniel E. Furst, MD, and Amy S. Chappell, MD, Pain Medicine, 1/1/2009
• Duloxetine 60 to 120 mg versus placebo in the treatment of patients with osteoarthritis knee pain  
  Chappell AS, Ossanna MJ, Liu-Seifert H, Collins H, Ann Rheum Dis, 1/1/2008
• Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, doubleblind,...  
  Russell IJ. Mease PJ. Smith TR. Kajdasz DK. Wohlreich MM. Detke MJ. Walker DJ. Chappell AS. Arnold LM, Pain, 1/1/2008
• An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain  
  Wernicke JF. Wang F. Pritchett YL. Smith TR. Raskin J. D'Souza DN. Iyengar S. Chappell AS, Pain Medicine, 1/1/2007
• Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review  
  Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS, Pain Medicine, 1/1/2007
• Fibromyalgia syndrome  
  Mease P. Arnold LM. Bennett R. Boonen A. Buskila D. Carville S. Chappell A. Choy E. Clauw D. Dadabhoy D. Gendreau M. Goldenberg D. Littlejohn G. Martin S. Perera P. Ru..., Journal of Rheumatology, 1/1/2007
• Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentrations in cerebrospinal fluid in healthy ...  
  SS Jhee, AS Chappell,V Zarotsky, SV Moran, M Rosenthal, E Kim, S Chalon,N Toublanc, J Brandt, DE Coutant, L Ereshefsky, Clin Pharmacology, 1/1/2006
• LY293558, a novel AMPA/GluR5 antagonist, is efficacious and welltolerated in acute migraine  
  Sang CN. Ramadan NM. Wallihan RG. Chappell AS. Freitag FG. Smith TR. Silberstein SD. Johnson KW. Phebus LA. Bleakman D. Ornstein PL. Arnold B. Tepper SJ. Vanderhende F., Cephalalgia, 1/1/2004
• Pearls and Pitfalls of Clinical Trial Investigation: Should I Get Involved in the Drug Development Process?  
  Chappell, AS, Seminars in Neurology, 1/1/2001
• Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats  
  Belayev L, Alonso OF, Liu Y, Chappell AS, Zhao W, Ginsberg MD, Busto R, Journal of Neurotrauma, 1/1/2001
• Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain  
  Max, M.B., Lee, G., Booher, S.L., Sang, C.N., Chappell, A.S., Dionne, R.A., Clinical Pharmacology and Therapeutics, 1/1/2000
• Join now to see all

Books/Book Chapters

• Alzheimer's Disease, A Physician's Guide to Practical Management 
  Chapter: AMPA Potentiator as a Treatment Option for Alzheimer's Disease 
  Amy S Chappell and Mike WitteEditors: Ralph W Richter and Brigitte Zoeller Richter.Humana Press, Totowa, New Jersey2004

Abstracts/Posters

• A double-blind, placebo-controlled study to investigate the efficacy and tolerability of intravenous 1.2 mg/kg LY293558 vs. 6 mg subcutaneous sumatriptan vs. placebo i...
  Sang CN, Ramadan NM, Chappell AS, Freitag FG, Smith TR, Silberstein SD, Tepper SJ, American Academy of Neurology Annual Meeting, 1/1/2001
• LY293558 an AMPA/KA receptor antagonist is effective in migraine
  Ramadan N, Sang C, Chappell A, Cephalalgia, 1/1/2001
• Overgrowth, Congenital Hypotonia, Nystagmus, Strabismus and Mental Retardation: A Possible Variant of Dominantly Inherited Sotos Sequence?
  Goldstein, D.J., Ward, R.E., Moore, E., Fremion, A.S., and Wappner, R.S., American J Medical Genetics, 1/1/1988
• Visual Function in World Class Tennis Players
  Fremion, A.S., DeMyer, W.E., Helveston, E., Miller, K., Sato, S., and Weber, J., Binocular Vision, 1/1/1986
• Maximum Oxygen Uptake Determination in Insulin Dependent Diabetes Mellitus
  Fremion, A.S., Marrero, D., Golden, M., Medicine and Science in Sport and Exercise, 1/1/1986
• Clinical Manifestations of Patients with Psyeudohypertrophic Muscular Dystrophy on Adenylosuccinic Acid Treatment
  Bonsett, C., Patel, V., Rudman, Al, Fremion, A.S., Clinical Research, 1/1/1986
• Visual Function in World Class Tennis Players
  Fremion, A.S., DeMyer, W.E., Helveston, E., Miller, K., Sato, S., and Weber, J., Olympic Scientific Congress, Eugene, Oregon, 1/1/1984
• NMR of Tuberous Sclerosis
  Edwards, M., Fremion, A.S., Garg, B.P. and Gilmore, R.L., Scientific Proceedings of the American Society of Neuroradiology, 1/1/1984
• Apnea as the Sole Manifestation of Cord Compression in Achondroplastic Dwarfs
  Fremion, A.S., Garg, B.P., and Kalsbeck, Neurology, 1/1/1983
• Tolerability and pharmacokinetics of LY451395, a selective AMPA receptor potentiator, in healthy subjects and patients with probable Alzheimer´s disease
  Pereira A, Chalon S, Cleton A, Jhee SS, Shiovitz TS, Kim E, Cutler NR, Chappell AS, 6th International Conference AD/PD, Seville, Spain, 1/8./2003
• The Outcome of Lennox-Gastaut
  Fremion, A.S., Ninth Annual Meeting of the Child Neurology Society, Savannah, Georgia, 1/2./1980
• LY450108 cerebrospinal fluid exposure in healthy human subjects
  Jhee SS, Chalon S, Toublanc N, Brandt J, Chappell A, Francisco M, 104th Meeting, American Society for Clinical Pharmacology and Therapeutics, Washington, DC, 1/2./2003
• Effects of rivastigmine on lorazepam-induced changes in EEG; a double-blind, placebo-controlled study
  Boeijinga PH, Chalon S, Granier LA, Staner L, Gilles C, Vandenhende F, Pereira A, Peck R, Chappell AS, 12th Biennial IPEG Meeting, Barcelona, Spain, 1/21/2002
• LY450108 cerebrospinal fluid pharmacokinetics in healthy human subjects
  Jhee SS, Chalon S, Toublanc N, Brandt J, Chappell A, Shiovitz TS, Francisco M, 32nd Annual Meeting, Society for Neuroscience, Orlando, FL, 1/2./2002
• Single Dose Safety, Tolerance, and Pharmacokinetics of LY451395, an AMPA potentiator, in Young Healthy Male Subjects
  Toublanc N, Chalon S, Pereira A, Zhang L, Decourt JP, Chappell A, 15th ECNP Congress, Barcelona, Spain, 1/5./2002
• Single Dose Safety, Tolerance, and Pharmacokinetics of LY450108, an AMPA potentiator, in Young Healthy Male Subjects
  Chalon S, Toublanc N, A. Pereira, Zhang L, Guillaume M, Chappell A, 15th ECNP Congress, Barcelona, Spain, 1/5./2002
• LY451395 cerebrospinal fluid pharmacokinetics in healthy human subjects
  Jhee SS, Chalon S, Toublanc N, Brandt J, Chappell A, Shiovitz TS, Farrar S, 31st Annual Meeting, American College of Clinical Pharmacology, San Francisco, CA, 1/21/2002
• Multiple-dose safety and tolerability of LY450108 and LY451395 in patients with probable Alzheimer’s disease (AD)
  Chappell AS, Toublanc N, Jhee SS, Shiovitz T, Kim E, Annual New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, 1/10/2002
• LY300164: A non-competitive AMPA receptor antagonist
  Chappell, AS, Fifth Eilat Conference On New Antiepileptic Drugs, 1/25/2000
• Analgesic Effects of AMPA/Kainate Antagonist LY293558 in Humans: Reduction of Capsaicin-Evoked Allodynia and Hyperalgesia but not Pain Sensations in Normal Skin
  Sang CN, Hostetter M, Gracely R, Chappell A, Lee G, Caruso, Whitcup S and Max MB, Society for Neuroscience, New Orleans, 1/27/1997
• Impact of a Home Exercise Program on Adolescent Metabolic Control and Fitness
  Marrero, D.G., Fremion, A.S., Golden, M., Diabetes Supplement: Proceedings of the 46th Annual Meeting of the American Diabetic Association, Anaheim, CA, 1/23/1986
• Join now to see all

Lectures

• Lifestyle Medicine to Improve Performance and Health 
  1/1/2016
• Challenges in Drug Development: Phase 2. What can go wrong when you think you have it right 
  1/1/2013
• Internationa10th IASP Research Symposium: The Genetics of Pain: Science, Medicine, & Drug Development 
  Pain Research Enterprises, Miami Beach, Florida - 2/7/2012
• Challenges in the Development of Putative Analgesics 
  1/1/2012
• Perspective of the Phamaceutical Industry on the Clinical Development of Analgesics 
  UCSD School of Medicine - 1/1/2010
• Brain Development and Teaching Tennis 
  Cincinnati, Ohio - 1/1/2008
• Risk Assessment of Compounds with Seizure Liability 
  San Diego, CA - 1/1/2006
• Playing Tennis in the Heat 
  Melbourne, Australia - 1/1/2000
• Discussion on Muscle Atrophy 
  Lyndon B. Johnson Space Center, Houston, Texas - 1/1/1986
• Clinical Experiences with AMPA/Kainate Antagonists 
  Manaus, Brazil - 1/18/1998
• Join now to see all